Actively Recruiting
Multimodal Assessment of Cognitive Impairment in Alzheimer Patients
Led by Norwegian University of Science and Technology · Updated on 2025-08-07
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying brain changes in people aged 65 and older with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The study aims to identify early signs that predict who will develop Alzheimer's, compare brain differences between healthy individuals and those with cognitive impairment, and distinguish variations among Alzheimer's patients. This observational research combines multiple methods to better understand these conditions. Participants will undergo several assessments including cognitive tests to evaluate brain function, magnetic resonance imaging (MRI) to examine structural and functional brain changes, and 64-channel electroencephalography (EEG) to measure brain electrical activity. Blood and fecal samples will be collected to analyze dementia-related proteins and gut bacterial composition. Additionally, a randomized subset of participants will have polysomnography to assess sleep patterns. Throughout the study, participants will be evaluated using cognitive interviews, neuroimaging scans, and biological sample analyses to monitor changes over time. The main outcomes tracked over five years include conversion from MCI to Alzheimer's and subtypes of Alzheimer's disease. The study involves healthy volunteers and includes control groups matched by age and gender, with ongoing monitoring by the Norwegian University of Science and Technology.
CONDITIONS
Brief Title
Multimodal Assesment of Alzheimer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD) according to relevant ICD criteria
- Control participants matched by age and gender with MCI and AD groups
- Age 65 years or older
You will not qualify if you...
- Unable to undergo planned neuroimaging tests such as MRI or EEG
- Diagnosis of Alzheimer's disease before age 65 (early-onset AD)
- Presence of brain tumor
- History of traumatic head injury
- Previous brain surgery
- Other neurodegenerative diseases like Parkinson's disease or ALS
- Diseases related to inflammation or auto-immunity such as multiple sclerosis (MS)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo MRI scanning, EEG, cognitive tests, and biological sample collection to assess brain changes and cognitive function.
1 to 2 visits depending on assessments
Duration - Up to 5 years
Participants are observed over time to monitor cognitive status and disease progression.
Annual visits for up to 5 years
Trial Site Locations
Total: 1 location
1
Norwegian University of Sciene and Technology / Norges teknisk-naturvitenskapelige universitet (NTNU)
Trondheim, Trønderlag, Norway, 7030
Actively Recruiting
Research Team
A
Axel Sandvig, Prof., MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here